Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.84 |
| ▸ | FNTB | P49356 | 19/20 | 0.84 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173299 | 0.92 | FNTA (0.82) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4562525 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4562526 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL7815392 | 0.89 | FNTA (0.84) | FNTAFNTBPGGT1B | |
| SCHEMBL6169332 | 0.89 | FNTA (0.84) | FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL6010278 | 0.85 | FNTA (0.90) | FNTAFNTBPGGT1B | |
| SCHEMBL3500901 | 0.84 | FNTA (0.70) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL6172871 | 0.84 | FNTA (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL7658457 | 0.82 | FNTA (0.84) | FNTAFNTBPGGT1B | |
| SCHEMBL6171864 | 0.82 | FNTA (0.72) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150973-B1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. | 2002-08-29 | — | — | US | claimed |
| CN-1340051-A | Heteroaryl-substituted quinoline-2-one derivatives useful asticancer agents | PFIZER PROD INC (US) | 2002-03-13 | — | — | CN | claimed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | claimed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | claimed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | claimed |
| EP-2545919-A1 | Treatment of synucleinopathies | Link Medicine Corporation (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| US-6388092-B2 | ANTITUMOR AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| CN-1340051-A | Heteroaryl-substituted quinoline-2-one derivatives useful asticancer agents | PFIZER PROD INC (US) | 2002-03-13 | — | — | CN | disclosed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | disclosed |
| US-20020004514-A1 | Anticancer compound and enantiomer separation method useful for synthesizing said compound | PFIZER PRODUCTS INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | FNTA 855/4885FNTB 2166/4885PGGT1B 692/4885 |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | FNTA 855/4885FNTB 2166/4885PGGT1B 692/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885PGGT1B 191/4885 |
| US-20020004514-A1 | Anticancer compound and enantiomer separation method useful for synthesizing said compound | HCCS, MCL1, CDKN1A | FNTA 1858/4885FNTB 4000/4885PGGT1B 1045/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885PGGT1B 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.